With a microfluidics platform designed for cell biology, the founders of Incept BioSystems realized that they had the opportunity to improve the quality of embryos destined for in vitro fertilization. IVF represents a great first market for a small medtech company; and larger markets in cell therapy loom ahead for Incept.
PO Box 4425
Ann Arbor, MI 48103
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.